BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co DSCR

The Debt Service Coverage Ratio (DSCR) of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 0.23. In the previous year, Debt Service Coverage Ratio (DSCR) was 0.16 — a change of 49.29% (higher).

DSCR

0.23

YoY

49.29%

Last updated:

Debt Service Coverage Ratio (DSCR) of BrightGene Bio-Medical Technology Co is 2025 0.23 . Debt Service Coverage Ratio (DSCR) of BrightGene Bio-Medical Technology Co was 2024 0.16 . It decreases by 49.29% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2020
2.01 CNY
Jan 1, 2021
0.28 CNY
Jan 1, 2022
0.20 CNY
Jan 1, 2023
0.12 CNY
Jan 1, 2024
0.16 CNY
Jan 1, 2025
0.23 CNY
The BrightGene Bio-Medical Technology Co DSCR history
YEARDSCRYoY
0.23+49.29%
0.16+30.08%
0.12-38.93%
0.20-30.61%
0.28-85.81%
2.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Debt Service Coverage Ratio (DSCR) of BrightGene Bio-Medical Technology Co is 0.23 in 2025.

Debt Service Coverage Ratio (DSCR) of BrightGene Bio-Medical Technology Co changed from 0.16 to 0.23, representing a 49.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co